乳腺癌紫杉醇耐药机制的研究进展  

Research on the mechanism of paclitaxel resistance in breast cancer

作　　者：石英香 王婧 石玉荣 杨清玲 Shi Yingxiang;Wang Jing;Shi Yurong;Yang Qingling(Anhui province key laboratory of translational cancer research,Bengbu Medical College,Bengbu,Anhui,233000,China;Department of biochemistry and molecular biology,School of laboratory medicine,Bengbu Medical College,Bengbu,Anhui,233000,China)

机构地区：[1]蚌埠医学院癌症转化医学安徽省重点实验室,安徽蚌埠233000 [2]蚌埠医学院检验医学院生物化学与分子生物学教研室,安徽蚌埠233000

出　　处：《齐齐哈尔医学院学报》2022年第6期557-561,共5页Journal of Qiqihar Medical University

基　　金：安徽省教育厅自然科学重大项目(KJ2019ZD28);蚌埠医学院研究生科研创新计划(Byycx21005)。

摘　　要：乳腺癌作为高度异质性肿瘤,单一化疗药物紫杉醇难以有效抑制癌症发展,在治疗后期频繁出现耐药状况。本文主要从药物排出蛋白表达、糖代谢改变和相关microRNA表达变化来探索紫杉醇耐药的潜在机制,进而探索克服紫杉醇耐药的新途径。除此之外,糖代谢改变还会诱发自噬,在调控乳腺癌紫杉醇耐药方面具有积极意义。本文回顾了在乳腺癌治疗中糖代谢改变对抗紫杉醇耐药的知识,以及糖酵解抑制剂和紫杉醇联合治疗在对抗紫杉醇耐药方面显示出的前景。Breast cancer is a highly heterogeneous tumor,single chemotherapy drug paclitaxel is difficult to effectively inhibit the development of cancer,drug resistance will often appear in the later stages of treatment.This research explores the possible mechanisms of paclitaxel resistance from drug excretion protein expression,glycose metabolism and related microRNA expression,and then explore new ways to overcome paclitaxel resistance.In addition,changes in glucose metabolism can also induce autophagy,which has positive significance in regulating paclitaxel resistance in breast cancer.We review the knowledge that changes in glucose metabolism contribute to resistance to paclitaxel in breast cancer treatment,and the promise that the combination therapy with glycolysis inhibitors and paclitaxel in overcome resistance to paclitaxel.

关 键 词：乳腺癌 PTX耐药 糖代谢 自噬 

分 类 号：R737.9[医药卫生—肿瘤]